AJN003 (LuCI™)
Type 2 Diabetes
Pre-clinicalAdvancing to Phase 1 (planned 2026)
Key Facts
About AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Eli Lilly | Approved |
| Orforglipron | Eli Lilly | Phase 3 |
| Trulicity (dulaglutide) | Eli Lilly | Approved |
| Forxiga | AstraZeneca | Approved |
| siRNA GalXC-GYS2 | Novo Nordisk | Phase 1 |
| Amylin/semaglutide combination | Novo Nordisk | Phase 3 |
| Lipaglyn | Zydus Lifesciences | Approved |
| LBS-009 | Belite Bio | Preclinical |
| Jentadueto (Linagliptin/Metformin) | Yuhan | Approved |
| Nesina (Alogliptin) | Yuhan | Approved |
| Metformin & Combinations | Ipca Laboratories | Commercial |
| GSBR-1290 | Structure Therapeutics | Phase 2 |